Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States

References

• Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122–9
   PubMed Web of Science ®Google Scholar
• Ascher-Svanum H, Zhu B, Faries DE, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 2010;10:2
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health. Numbers count: mental disorders in America. 2013. www.nimh.nih.gov/health/publications/the-numbers-count-mental-disorders-in-america/index.shtml#Schizophrenia. Accessed December 19, 2013
   Google Scholar
• Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241–7
   PubMed Web of Science ®Google Scholar
• Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J Clin Psychiatry 2003;64(16 Suppl):14–17
   Google Scholar
• Schennach R, Obermeier M, Meyer S, et al. Predictors of relapse in the year after hospital discharge among patients with schizophrenia. Psychiatr Serv 2012;63:87–90
   PubMed Web of Science ®Google Scholar
• Hasan A, Falkai P, Wobrock T, et al; WFSBP Task force on Treatment Guidelines for Schizophrenia. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2–44
   PubMed Web of Science ®Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. American Psychiatric Association, http://psychiatryonline.org/content.aspx?bookID=28&sectionID=1665359. Accessed December 20, 2013
   Google Scholar
• Lehman AF, Lieberman JA, Dixon LB, et al; American Psychiatric Association; Steering Committee on Practice Guidelines. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2 Suppl):1–56
   PubMed Web of Science ®Google Scholar
• Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004;30:193–217
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Scheifler PL, Frances A. Expert consensus guideline series: treatment of schizophrenia 1999. J Clin Psychiatry 1999;60(11 Suppl):1–80
   Google Scholar
• International Psychopharmacology Algorithm Project. www.ipap.org. Accessed December 19, 2013
   Google Scholar
• Moore TA. Schizophrenia treatment guidelines in the United States. Clin Schizophr Relat Psychoses 2011;5:40–9
   Google Scholar
• Kane JM, Garcia-Ribera C. Clinical guideline recommendations for antipsychotic long-acting injections. Br J Psychiatry Suppl 2009;52:S63–7
   PubMedGoogle Scholar
• Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013;74:957–65
   Google Scholar
• Rossi G, Frediani S, Rossi R, et al. Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations. BMC Psychiatry 2012;12:122
   Google Scholar
• Citrome L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother 2013;13:767–83
   PubMed Web of Science ®Google Scholar
• Peng X, Ascher-Svanum H, Faries D, et al. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res 2011;3:9–14
   PubMedGoogle Scholar
• Olfson M, Marcus SC, Ascher-Svanum H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol, or risperidone. Schizophr Bull 2007;33:1379–87
   PubMed Web of Science ®Google Scholar
• Otsuka Pharmaceutical Company Inc. Aripiprazole prescribing information. 2013. Available at: http://www.otsuka-us.com/Documents/Abilify.PI.pdf. [Last accessed April 2014]
   Google Scholar
• Janssen Pharmaceuticals Inc. Paliperidone palmitate injectable prescribing information. 2012. Available at: http://www.invegasustenna.com/pdf/invegasustenna-prescribing-info.pdf [Last accessed April 2014]
   Google Scholar
• Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia a systematic review of economic evaluations. Appl Health Econ Health Policy 2013;11:95–106
   PubMedGoogle Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. New York: Oxford University Press, 2005
   Google Scholar
• Janssen Pharmaceuticals Inc. Risperidone long-acting injection prescribing information. 2012. Available at: http://www.janssencns.com/risperdal/risperdal-prescribing-information. [Last accessed April 2014]
   Google Scholar
• Kane J, Sanchez R, Perry PP, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;75:617–24
   Google Scholar
• Hough D, Gopal S, Vijapurkar U, et al. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 2010;116:107–17
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2014;40:192–213
   PubMed Web of Science ®Google Scholar
• Viguera AC, Baldessarini RJ, Hegarty JD, et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997;54:49–55
   PubMed Web of Science ®Google Scholar
• Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizoph Res 2004;71:155–65
   PubMed Web of Science ®Google Scholar
• Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr Med Res Opin 2011;27:713–30
   PubMed Web of Science ®Google Scholar
• APP Pharmaceuticals LLC. Fluphenazine decanoate injection prescribing information. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/071413s019lbl.pdf [Last accessed April 2014]
   Google Scholar
• Ortho-McNeil-Janssen Pharmaceuticals. Haloperidol decanoate injection prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018701s054lbl.pdf [Last accessed April 2014]
   Google Scholar
• Kelly DL, Wehring HJ, Earl AK, et al. Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic Elevated prolactin). BMC Psychiatry 2013;13:214
   PubMed Web of Science ®Google Scholar
• Medi-Span Price Rx.® https://pricerx.medispan.com/ProductName.aspx. Accessed December 19, 2013
   Google Scholar
• US Department of Labor. Bureau of Labor Statistics. Archived consumer price index detailed report information. www.bls.gov/cpi/cpi_dr.htm. Accessed December 19, 2013
   Google Scholar
• US Department of Health & Human Services. Agency for Healthcare Research and Quality. HCUPnet. http://hcupnet.ahrq.gov. Accessed December 19, 2013
   Google Scholar
• US Department of Labor. Consumer Price Inflator. www.bls.gov/cpi#data. Accessed March 28, 2014
   Google Scholar
• Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005;23(1 Suppl):75–89
   PubMedGoogle Scholar
• US Department of Labor. Occupational employment statistics. www.bls.gov/oes/current/oes_nat.htm#29-0000. Accessed March 2, 2014
   Google Scholar
• US Department of Health and Human Services. Agency of Healthcare Research home page. http://hcupnet.ahrq.gov/HCUPnet.jsp?Id=D19601906527E991&Form=SelCROSSTAB&JS=Y&Action=%3E%3ENext%3E%3E&_Oneway=Yes. Accessed March 28, 2014
   Google Scholar
• Kamat S, Gutierrez B, Eramo A, et al. Initial assessment of real-world usage of extended-release injectable paliperidone palmitate among medicaid insured schizophrenia patients. Value Health 2013;16:A61
   Google Scholar
• Abouzaid S, Jutkowitz E, Foley KA, et al. Economic impact of prior authorization policies for atypical antipsychotics in the treatment of schizophrenia. Popul Health Manag 2010;13:247–54
   PubMed Web of Science ®Google Scholar
• Gitlin M, Neuchterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry 2001;158:1835–42
   PubMed Web of Science ®Google Scholar
• Soumerai SB, Zhang F, Ross-Degnan D, et al. Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Aff (Millwood) 2008;27:w185–95
   Web of Science ®Google Scholar
• Law MR, Ross-Degnan D, Soumerai SB. Effect of prior authorization of second-generation antipsychotic agents on pharmacy utilization and reimbursements. Psychiatr Serv 2008;59:540–6
   Web of Science ®Google Scholar
• Tunis SL, Faries DE, Nyhuis AW, et al. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health 2006;9:77–89
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886–91
   PubMed Web of Science ®Google Scholar
• Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 2009;10:1917–28
   PubMed Web of Science ®Google Scholar